Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389323 | 1.00 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL389757 | 0.93 | GPR119 (0.87) | GPR119CYP2C9KCNH2 | |
| SCHEMBL391455 | 0.90 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL5208216 | 0.90 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390398 | 0.89 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL391113 | 0.89 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL389390 | 0.89 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL18538619 | 0.89 | GPR119 (0.80) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1245468 | 0.88 | GPR119 (0.79) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12505331 | 0.88 | GPR119 (0.78) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250276989-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025136929-A1 | GPR40 AGONISTS | KALLYOPE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-3827829-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING NONALCOHOLIC FATTY LIVER DISEASE, CONTAINING A GPR119 LIGAND AS ACTIVE INGREDIENT | DONG A ST CO LTD (KR) | 2025-05-07 | — | — | EP | disclosed |
| US-12264171-B2 | GPR40 agonists | KALLYOPE, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-114945560-B | GPR119 agonists | 卡尔优普公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-20240217983-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11407768-B2 | AMPK activators | KALLYOPE, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220227754-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220226298-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11376257-B2 | Generation of muscle lineage cells and therapeutic uses thereof | SONIC MASTER LIMITED (VG) | 2022-07-05 | — | — | US | disclosed |
| US-11358956-B2 | Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2022-06-14 | — | — | US | disclosed |
| US-20220153719-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3976576-A1 | GPR40 AGONISTS | Kallyope, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11279702-B2 | AMPK activators | KALLYOPE, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220033401-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264171-B2 | GPR40 agonists | GPR119, GPR65, GLP1R | GPR119 1/4885CYP2C9 3310/4885KCNH2 4622/4885 |
| US-20250276989-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | GPR119 1/4885CYP2C9 3310/4885KCNH2 4622/4885 |
| US-20220227754-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAG3 | GPR119 11/4885CYP2C9 4846/4885KCNH2 4281/4885 |
| US-11279702-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAG3 | GPR119 11/4885CYP2C9 4846/4885KCNH2 4281/4885 |
| US-20220226298-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | GPR119 1/4885CYP2C9 3310/4885KCNH2 4622/4885 |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | WNT3, TRPV3, ADRB3 | GPR119 2147/4885CYP2C9 73/4885KCNH2 708/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | GPR119 4238/4885CYP2C9 3502/4885KCNH2 4880/4885 |
| US-11376257-B2 | Generation of muscle lineage cells and therapeutic uses thereof | MYLK2, MUSK, CKMT1A; CKMT1B | GPR119 926/4885CYP2C9 4846/4885KCNH2 4462/4885 |
| US-20240217983-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | GPR119 1/4885CYP2C9 2350/4885KCNH2 4507/4885 |
| US-20220033401-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAG3 | GPR119 11/4885CYP2C9 4846/4885KCNH2 4281/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | GPR119 4238/4885CYP2C9 3502/4885KCNH2 4880/4885 |
| US-11407768-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAA1 | GPR119 10/4885CYP2C9 4825/4885KCNH2 4241/4885 |
| US-11358956-B2 | Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR27, GCGR | GPR119 1/4885CYP2C9 1086/4885KCNH2 941/4885 |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR3, GPR39 | GPR119 1/4885CYP2C9 1167/4885KCNH2 2202/4885 |
| US-20220153719-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | GPR119 1/4885CYP2C9 2350/4885KCNH2 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.